Merck Projects 2026 Revenue Between $66.8B and $67.3B Amid Keytruda Transition Strategy
Merck & Co., Inc. (MRK) reported third-quarter revenue of $18.1 billion, driven by strong performance in its Oncology and Animal Health segments. CEO Robert Davis noted that the company's growth is being bolstered by increased contributions from new product launches. Looking ahead to 2026, Merck has provided financial guidance projecting annual revenue between $66.8 billion and $67.3 billion, with earnings per share (EPS) expected in the range of $2.77 to $2.82. These projections come as the company strategically invests to mitigate the impact of the upcoming Loss of Exclusivity (LOE) for its blockbuster drug, Keytruda.
Tickers: $MRK
Topics: animal health earnings oncology revenue